Inês Tribolet de Abreu

Inês Tribolet de Abreu

Auto-generated profile, based on publicly available information

Inês Tribolet de Abreu

Unidade Local de Saúde Santa Maria

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
PDF file
GAGustavo Almeida-Silva
Gustavo Almeida-Silva
JAJoana Antunes
Joana Antunes
IAInês Tribolet de Abreu
Inês Tribolet de Abreu
FMFilipe Monteiro
Filipe Monteiro
PVPedro Vasconcelos
Pedro Vasconcelos
PFPaulo Filipe
Paulo Filipe
Sweet’s syndrome (or acute febrile dermatosis) is a neutrophilic dermatosis with a characteristic presentation encompassing specific clinical (fever and erythemato-violaceous oedematous papules, plaques and nodules), laboratory (neutrophilia and increased inflammatory markers), and histological (dermal neutrophilic infiltrate without vasculitis) features. Its pathophysiology is poorly understood but there seems to be an auto-inflammatory component related to mutations in inflammasome genes. It has been subdivided into its classic form, malignancy-associated, and drug-induced, according to its aetiology. The condition usually responds rapidly to steroid therapy, but recurrences are common. This report presents an extremely rare case of hydroxychloroquine-induced Sweet’s syndrome, plus a review of the literature, which encompasses 3 previous cases of Sweet’s syndrome induced by hydroxychloroquine and 1 induced by chloroquine. Despite being relatively easy to diagnose, aetiological investigation poses challenges to the clinician, especially in the elderly population, as several confounding factors might be present. Further studies are necessary to shed light on the pathophysiology behind this entity, to further facilitate diagnostic workup and treatment strategies.

8 March 2026 in International Immunopharmacology
Verified
Journal Article
Closed access
ITInês Tribolet-De-Abreu
Inês Tribolet-De-Abreu
IPInês Pereira-Amaral
Inês Pereira-Amaral
PFPaulo Filipe
Paulo Filipe

2 June 2025 in Acta Medica Portuguesa
Verified
Journal Article
Open access
IAInês Tribolet de Abreu
Inês Tribolet de Abreu
PVPedro De Vasconcelos
Pedro De Vasconcelos
RCRafael Moiteiro da Cruz
Rafael Moiteiro da Cruz
LSLuis Soares-de-Almeida
Luis Soares-de-Almeida
PFPaulo Filipe
Paulo Filipe

20 June 2025 in Acta Medica Portuguesa
Verified
Journal Article
Open access
IAInês Pereira Amaral
Inês Pereira Amaral
ISIvânia Soares
Ivânia Soares
MCMadalena Pupo Correia
Madalena Pupo Correia
IAInês Tribolet Abreu
Inês Tribolet Abreu
FMFilipe Monteiro
Filipe Monteiro
PFPaulo Filipe
Paulo Filipe
Introduction: Kaposi’s sarcoma (KS) is a rare angioproliferative neoplasm associated with human herpesvirus 8 infection, presenting as four subtypes: classic, endemic, iatrogenic, and epidemic. While well documented globally, comprehensive data on KS in Portugal remain scarce. The aim of this retrospective study was to provide a detailed analysis of KS cases diagnosed at Hospital Santa Maria, in Lisbon, between 2014 and 2023.Methods: A total of 113 histopathologically confirmed KS cases were included, focusing on demographic, clinical, and histopathological characteristics, as well as treatment strategies and outcomes.Results: The mean age at diagnosis was 59.4 years, with a male-to-female ratio of 4.4:1. Most patients (50.4%) were of African origin. Epidemic KS (45.1%) was the most prevalent subtype. Lesions mainly affected the lower limbs (47.8%), and disseminated, mucosal, and extracutaneous involvement were more common in HIV-positive patients. Tumor-stage lesions were frequent (59.3%). Single-modality treatment was used in 53.1% of cases, while 40.7% required combined therapies. Relapse rates were highest in endemic (39.1%) and iatrogenic KS (28.6%) subtypes. The disease-specific mortality rate was 8%.Conclusion: Our findings suggest that KS remains a significant concern, particularly in immunosuppressed patients. Early diagnosis and multidisciplinary management are essential to improve outcomes. However, limitations such as potential biases from its retrospective design and the single-center scope should be considered.

16 December 2025 in Photochemical & Photobiological Sciences
Verified
Journal Article
Closed access
PDF file
IAInês Tribolet de Abreu
Inês Tribolet de Abreu
RSRené Santus
René Santus
JFJoão Ferreira
João Ferreira
PFPaulo Filipe
Paulo Filipe

23 February 2026 in Drugs in Context
Verified
Journal Article
Open access
GAGustavo Almeida-Silva
Gustavo Almeida-Silva
IAInês Tribolet de Abreu
Inês Tribolet de Abreu
FMFilipe Monteiro
Filipe Monteiro
PVPedro de Vasconcelos
Pedro de Vasconcelos
PFPaulo Filipe
Paulo Filipe
JAJoana Antunes
Joana Antunes
The authors provide a concise narrative review of biologic-induced cutaneous pseudolymphomas and illustrate the topic with the first reported case of brodalumab-induced pseudolymphoma in a patient with psoriasis.